Is TECH a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Pending Merck KGaA acquisition, with situation at Pending acquisition by Merck KGaA at $73 per share in cash (announced June 25, 2026); verify live figures and deal status before acting. The bear case rests on the central risk is deal-specific: because the stock trades near the $73 cash offer, a failure to close (from regulatory objections, the shareholder vote, or a change in conditions) could send shares back toward pre-announcement levels, while the upside above the deal price is limited. Analysts covering it are spread from $50.00 to $73.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central risk is deal-specific: because the stock trades near the $73 cash offer, a failure to close (from regulatory objections, the shareholder vote, or a change in conditions) could send shares back toward pre-announcement levels, while the upside above the deal price is limited. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $50.00, -30.7% from the $72.14 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Pending Merck KGaA acquisition. The dominant driver is the June 2026 agreement for Merck KGaA to acquire Bio-Techne for $73 per share in cash. The most optimistic analyst target on TECH is $73.00, +1.2% from the $72.14 price. That figure is only reachable if this thesis works close to its best case.

The central risk is deal-specific: because the stock trades near the $73 cash offer, a failure to close (from regulatory objections, the shareholder vote, or a change in conditions) could send shares back toward pre-announcement levels, while the upside above the deal price is limited. Timing risk matters too, since the money is tied up until the transaction completes in late 2026 or early 2027. If the deal fell through, the stock would again trade on fundamentals, where organic growth in Protein Sciences has been soft and demand depends on biotech and academic funding cycles that remain under pressure. Foreign-exchange swings, integration uncertainty for the combined entity, and the general execution risk of a large cross-border merger add further variables outside an individual investor's control. The most pessimistic published target is $50.00, -30.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Bio-Techne Corporation is a global life-sciences tools and diagnostics company based in Minnesota.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Pending Merck KGaA acquisition) stalling in the reported numbers rather than in the narrative, the risk above (the central risk is deal-specific: because the stock trades near the $73 cash offer, a failure to close (from regulatory objections, the shareholder vote, or a change in conditions) could send shares back toward pre-announcement levels, while the upside above the deal price is limited) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. In mid-2026 Bio-Techne is subject to a pending $73-per-share cash takeover by Merck KGaA, and the stock trades near that price. So buying now is mostly a bet on the deal closing (limited upside above $73, downside if it breaks) rather than on the underlying business. Weigh the merger odds, timing, and your risk tolerance against your portfolio.

Bio-Techne is a life-sciences tools and diagnostics company, not a generic technology firm despite the TECH ticker. It makes reagents, proteins, antibodies, and immunoassays, sells spatial-biology instruments such as its COMET platform, and runs a precision-diagnostics business. Its customers are biopharma and academic researchers, so it supplies the consumables and instruments used upstream in drug discovery, cell therapy, and diagnostics.

On June 25, 2026, Merck KGaA (the German science and technology group) agreed to acquire Bio-Techne for $73 per share in cash, an enterprise value of roughly $11.3 billion. The deal strengthens Merck KGaA's life-science division by adding Bio-Techne's reagents, spatial-biology, and multi-omics tools, which sit upstream of drug discovery and biomanufacturing. It is expected to close in late 2026 or early 2027, subject to regulatory approvals and a shareholder vote.